ArticleNucleic acids research2006
Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.
Article in Nucleic acids research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 112 citations in OpenAlex.
- Cell-cycle-specific lesion evolution rather than inhibition of double-strand-break repair underpins cisplatin radiosensitization.Molecular oncology · 2026Article
- HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells.Cancers · 2021Article
- History and emerging trends in chemotherapy for gastric cancer.Annals of gastroenterological surgery · 2021Review
- Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells.Histochemistry and cell biology · 2020Article
- Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells.Molecular oncology · 2020Article
- Long-term, genome-wide kinetic analysis of the effect of the circadian clock and transcription on the repair of cisplatin-DNA adducts in the mouse liver.The Journal of biological chemistry · 2019Article
- Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs.Nature communications · 2019Article
- Imaging cellular responses to antigen tagged DNA damage.DNA repair · 2018Review
- The circadian clock regulates cisplatin-induced toxicity and tumor regression in melanoma mouse and human models.Oncotarget · 2018Article
- Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.International journal of molecular sciences · 2018Article
- Sequence-Independent DNA Nanogel as a Potential Drug Carrier.Macromolecular rapid communications · 2017Article
- Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.Breast cancer research : BCR · 2017Article
- ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.Cancer research · 2017Article
- Vasculogenic mimicry in small cell lung cancer.Nature communications · 2016Article
- Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues.Scientific reports · 2016Article
- Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2016Article
- Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.Oncotarget · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The anticancer drug cisplatin executes its cytotoxic activity via formation of intra- and interstrand crosslinks in DNA. The relative contribution of structurally defined cisplatin adducts to induce apoptosis and the cellular processing of these lesions is still poorly understood mostly due to the lack of sensitive analytical tools for in vivo studies. Here we describe a new method to establish and characterize monoclonal antibodies (Mab) for structurally defined DNA adducts. The two major reaction products of cisplatin, the guanine-guanine (Pt-[GG]) and adenine-guanine (Pt-[AG]) intrastrand crosslinks are recognized by Mab R-C18 and R-B3, respectively. Both antibodies were employed in an immuno-cytological assay allowing the quantification of drug-induced lesions in individual cell nuclei at clinically relevant doses. Analyzing various tissues of cisplatin-treated C57Bl/6 mice the accumulation of Pt-(GG) was highest in kidney tubular cells compared with 30, 50 and 90% lower levels in kidney stroma, liver and peripheral blood cells, respectively. Adduct kinetics revealed that wild type mouse cells remove up to 80% of the crosslinks in contrast to their complete persistence in nucleotide excision repair-deficient (XPC-/-) mice. The aptitude of the immunoassay for human molecular dosimetry studies was demonstrated by measuring adduct levels in tumor biopsies from patients treated with cisplatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.